Valuation: Monte Rosa Therapeutics, Inc.

Market Cap 775M 707M 654M 590M 1.11B 72.42B 1.15B 7.89B 3.12B 39.09B 2.91B 2.85B 123B P/E 2026 *
-8.58x
P/E 2027 * -4.95x
Enterprise Value 236M 215M 199M 180M 338M 22.06B 352M 2.4B 950M 11.91B 885M 867M 37.59B EV / Sales 2026 *
2.31x
EV / Sales 2027 * 4.25x
Free-Float
99.25%
Yield 2026 *
-
Yield 2027 * -
1 day+1.87%
1 week-11.45%
Current month-15.15%
1 month-14.35%
3 months-39.25%
6 months-49.31%
Current year-41.77%
1 week 8.83
Extreme 8.83
10.28
1 month 8.83
Extreme 8.83
11.74
Current year 8.83
Extreme 8.83
25.77
1 year 8.83
Extreme 8.83
25.77
3 years 2.91
Extreme 2.9106
25.77
5 years 2.44
Extreme 2.44
25.77
10 years 2.44
Extreme 2.44
45.56
Manager TitleAgeSince
Chief Executive Officer 55 31/12/2019
Chief Tech/Sci/R&D Officer - 16/03/2026
Chief Operating Officer 54 28/02/2021
Director TitleAgeSince
Director/Board Member 55 31/12/2019
Director/Board Member 49 31/03/2020
Director/Board Member 57 31/05/2020
Date Insider Type Main position Quantity % Market Cap. Importance
05/10/26 Sell

Controller/Auditor

-13 0.0000%
16/07/26 Sell

Chief Executive Officer

-9,500 0.0112%
15/07/26 Exercice

Chief Operating Officer

13,053 0.0155%
Change 5-day change 1-year change 3-year change Capi.($)
+1.65%-11.45%-33.74%+180.92% 775M
-1.34%-4.12%+53.70%+68.83% 66.37B
+0.59%-1.83%+8.98%+90.68% 58.86B
+0.54%+0.45%+25.96%+86.62% 55.22B
-1.95%-3.55%+11.31%+115.60% 47.21B
+0.41%-6.20%+18.52%+25.44% 42.45B
-2.58%+2.22%+14.73%+41.28% 36.44B
-1.14%-11.07%+127.68%+639.51% 35.19B
-0.17%-1.83%+82.46%+57.48% 32.66B
-0.84%+0.16%-40.01%+391.25% 26.73B
Average -0.43%-4.02%+26.96%+169.76% 40B
Weighted average by Cap. -0.63%-2.94%+33.52%+143.59%

Financials

2026 *2027 *
Net sales 102M 93.27M 86.23M 77.82M 147M 9.56B 152M 1.04B 412M 5.16B 384M 376M 16.29B 62.16M 56.69M 52.42M 47.31M 89.09M 5.81B 92.61M 633M 250M 3.14B 233M 228M 9.9B
Net income -107M -97.4M -90.06M -81.27M -153M -9.98B -159M -1.09B -430M -5.39B -401M -392M -17.01B -194M -177M -164M -148M -278M -18.12B -289M -1.97B -781M -9.78B -728M -712M -30.89B
Net Debt -539M -492M -455M -410M -772M -50.37B -803M -5.49B -2.17B -27.19B -2.02B -1.98B -85.85B -511M -466M -431M -389M -732M -47.71B -761M -5.2B -2.06B -25.75B -1.92B -1.88B -81.32B
Projected Income Statement - Annual - Monte Rosa Therapeutics, Inc.
Logo Monte Rosa Therapeutics, Inc.
Monte Rosa Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing a portfolio of novel and molecular glue degraders (MGDs). MGDs are small molecule drugs that employ the body’s natural protein destruction mechanisms to selectively degrade therapeutically relevant proteins. It has developed a proprietary and industry leading discovery engine, called Quantitative and Engineered Elimination of Neosubstrates (QuEEN) to enable its target centric MGD discovery and development approach and its rational design of MGD product candidates. Its product candidate, MRT-2359, is an orally bioavailable MGD targeting the translation termination factor protein GSPT1. MRT-2359 is in clinical development for potential use in MYC-driven tumors, including metastatic non-small cell lung cancer, small cell lung cancer, and neuroendocrine tumors. Its other product candidates include MRT-6160 and MRT-8102.
Employees
185
Date Price Change Volume
18/11/26 US$9.200 +1.43% 368,916
17/11/26 US$9.070 -0.98% 1,176,563
16/11/26 US$9.160 -2.24% 881,028
13/11/26 US$9.370 +0.64% 1,119,299
12/11/26 US$9.310 -9.70% 1,245,710
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
MarketScreener Ratings - Monte Rosa Therapeutics, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
9.070USD
Average target price
25.38USD
Spread / Average Target
+179.77%
  1. Stock Market
  2. Stocks
  3. GLUE Stock